Zidovudine

Overview

Journal Infect Dis Obstet Gynecol

Publisher Wiley

Specialties Gynecology & Obstetrics
Infectious Diseases

Date 1999 Jan 23

PMID 9894173

Citations 11

Authors

R Sperling

Affiliations

Soon will be listed here.

Abstract

Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987, the pharmacokinetic disposition and clinical effects of ZDV have been extensively evaluated. In addition to its utility as a component of a multidrug combination regimen for the treatment of adult and pediatric HIV-1 infection, it is the only agent approved by the FDA for the prevention of mother-to-child HIV-1 transmission. The effectiveness of ZDV for the prevention of mother-to-child HIV-1 transmission has been demonstrated in several studies. The optimal time during gestation to initiate ZDV therapy and the relative importance of the intrapartum and newborn components is the focus of both current interventional and observational studies. Until more information is available from these trials, the combined maternal/newborn ZDV regimen studied in ACTG 076 remains the recommended treatment regimen of choice in the United States.

Citing Articles

A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy.

Hanser S, Choshi J, Mokoena H, Mabhida S, Mchiza Z, Moetlediwa M Front Med (Lausanne). 2024; 11:1295217.

PMID: 38566923 PMC: 10985183. DOI: 10.3389/fmed.2024.1295217.

Antiviral Effect of 5'-Arylchalcogeno-3-aminothymidine Derivatives in SARS-CoV-2 Infection.

Tucci A, da Rosa R, Rosa A, Augusto Chaves O, Ferreira V, Oliveira T Molecules. 2023; 28(18).

PMID: 37764472 PMC: 10537738. DOI: 10.3390/molecules28186696.

Magnetic triazine-based dendrimer as a versatile nanocarrier for efficient antiviral drugs delivery.

Ahangarani-Farahani R, Bodaghifard M, Asadbegi S Sci Rep. 2022; 12(1):19469.

PMID: 36376529 PMC: 9662132. DOI: 10.1038/s41598-022-24008-9.

In vitro anti-HIV and cytotoxic effects of pure compounds isolated from Croton macrostachyus Hochst. Ex Delile.

Terefe E, Okalebo F, Derese S, Langat M, Mas-Claret E, Aljarba N BMC Complement Med Ther. 2022; 22(1):159.

PMID: 35705943 PMC: 9202147. DOI: 10.1186/s12906-022-03638-6.

Giardia intestinalis thymidine kinase is a high-affinity enzyme crucial for DNA synthesis and an exploitable target for drug discovery.

Krakovka S, Ranjbarian F, Lujan L, Saura A, Larsen N, Jimenez-Gonzalez A J Biol Chem. 2022; 298(6):102028.

PMID: 35568200 PMC: 9190010. DOI: 10.1016/j.jbc.2022.102028.

References

Sperling R, ROBOZ J, DISCHE R, SILIDES D, Holzman I, Jew E . Zidovudine pharmacokinetics during pregnancy. Am J Perinatol. 1992; 9(4):247-9. DOI: 10.1055/s-2007-994781. View

Watts D, Brown Z, Tartaglione T, Burchett S, Opheim K, Coombs R . Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991; 163(2):226-32. DOI: 10.1093/infdis/163.2.226. View

Liebes L, Mendoza S, Wilson D, DANCIS J . Transfer of zidovudine (AZT) by human placenta. J Infect Dis. 1990; 161(2):203-7. DOI: 10.1093/infdis/161.2.203. View

Reynolds F, Knott C . Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol. 1989; 11:389-449. View

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

KRAUER B, Krauer F, HYTTEN F . Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther. 1980; 10(2):301-28. DOI: 10.1016/0163-7258(80)90085-6. View

Frenkel L, Wagner 2nd L, Demeter L, Dewhurst S, Coombs R, Murante B . Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995; 20(5):1321-6. DOI: 10.1093/clinids/20.5.1321. View

Matheson P, Abrams E, Thomas P, Hernan M, Thea D, Lambert G . Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis. 1995; 172(2):353-8. DOI: 10.1093/infdis/172.2.353. View

Connor E, Sperling R, Gelber R, Kiselev P, Scott G, OSullivan M . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. DOI: 10.1056/NEJM199411033311801. View

10.

OSullivan M, Boyer P, SCOTT G, Parks W, Weller S, Blum M . The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082)..... Am J Obstet Gynecol. 1993; 168(5):1510-6. DOI: 10.1016/s0002-9378(11)90791-1. View

11.

Fiscus S, Adimora A, Schoenbach V, Lim W, McKinney R, Rupar D . Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996; 275(19):1483-8. View

12.

Mauskopf J, Paul J, Wichman D, White A, Tilson H . Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA. 1996; 276(2):132-8. View

13.

Acosta E, Schwebke K, Henry K, Fletcher C . Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. J Infect Dis. 1996; 174(3):673. DOI: 10.1093/infdis/174.3.673. View

14.

Sperling R, Shapiro D, Coombs R, Todd J, Herman S, McSherry G . Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996; 335(22):1621-9. DOI: 10.1056/NEJM199611283352201. View

15.

Acosta E, Page L, Fletcher C . Clinical pharmacokinetics of zidovudine. An update. Clin Pharmacokinet. 1996; 30(4):251-62. DOI: 10.2165/00003088-199630040-00001. View

16.

Ayers K, Torrey C, Reynolds D . A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol. 1997; 38(2):195-8. DOI: 10.1006/faat.1997.2342. View

17.

Eastman P, Shapiro D, Coombs R, Frenkel L, McSherry G, Britto P . Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis. 1998; 177(3):557-64. DOI: 10.1086/514228. View

18.

CARPENTER C, Fischl M, Hammer S, Hirsch M, Jacobsen D, Katzenstein D . Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998; 280(1):78-86. DOI: 10.1001/jama.280.1.78. View

19.

Sperling R, Shapiro D, McSherry G, Britto P, Cunningham B, Culnane M . Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS. 1998; 12(14):1805-13. DOI: 10.1097/00002030-199814000-00012. View